Trexquant Investment LP Purchases New Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Trexquant Investment LP purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 80,907 shares of the medical equipment provider's stock, valued at approximately $7,238,000. Trexquant Investment LP owned 0.12% of Lantheus at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. State of New Jersey Common Pension Fund D grew its holdings in shares of Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after purchasing an additional 115 shares during the last quarter. Bleakley Financial Group LLC grew its position in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after buying an additional 129 shares during the period. Avantax Advisory Services Inc. raised its stake in shares of Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after buying an additional 132 shares during the last quarter. UMB Bank n.a. lifted its holdings in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Finally, Aurora Investment Counsel boosted its stake in Lantheus by 0.8% in the fourth quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock valued at $1,718,000 after acquiring an additional 146 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Up 7.2 %

Shares of NASDAQ LNTH traded up $6.75 during mid-day trading on Wednesday, reaching $100.16. 958,422 shares of the company's stock were exchanged, compared to its average volume of 952,235. Lantheus Holdings, Inc. has a twelve month low of $58.46 and a twelve month high of $126.89. The business has a fifty day simple moving average of $93.62 and a 200 day simple moving average of $95.76. The firm has a market capitalization of $6.86 billion, a price-to-earnings ratio of 16.67 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have commented on LNTH shares. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price for the company. Truist Financial upped their price objective on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.